Quick Answer
Milestone Pharmaceuticals Inc. reported Cash and Equivalents of $73.05 million for fiscal year 2025.
Milestone Pharmaceuticals Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $73.05M | +188.6% |
| 2024 | $25.31M | +84.0% |
| 2023 | $13.76M | +80.2% |
| 2022 | $7.64M | -93.3% |
| 2021 | $114.14M | +57.8% |
| 2020 | $72.31M | -39.7% |
| 2019 | $119.82M | +39.4% |
| 2018 | $85.95M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $46.69M | +264.8% | +9.8% |
| June 30, 2025 | $42.50M | +220.5% | -5.7% |
| March 31, 2025 | $45.09M | +345.0% | +78.1% |
| December 31, 2024 | $25.31M | +84.0% | +97.8% |
| September 30, 2024 | $12.80M | +29.6% | -3.5% |
| June 30, 2024 | $13.26M | -59.3% | +30.9% |
| March 31, 2024 | $10.13M | -86.3% | -26.4% |
| December 31, 2023 | $13.76M | +80.2% | +39.3% |
- Milestone Pharmaceuticals Inc. showed an increase of +188.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Milestone Pharmaceuticals Inc.’s cash and equivalents has declined by 15.0% (from $85.95 million to $73.05 million).
- The most recent figure is from Milestone Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: